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MITOMYCIN C-INDUCED RENAL INSUFFICIENCY:
A CASE REPORT
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A 58-year-old normotensive male with normal renal function and gastric cancer underwent
total gastrectomy and received adjuvant chemotherapy with mitomycin C (MMC) for 10
months. He developed anemia, hypertension, and renal function impairment 9 months after
initiation of chemotherapy. Kidney biopsy showed thrombotic microangiopathy with marked
mesangiolysis and expansion of the subendothelial space resulting in cystic dilation of the
glomerular capillaries, and cellular atypia in the tubular cells. His renal function deteriorated
gradually then stabilized after treatment with plasma exchange, antihypertensive agents,
and antiplatelet agents. He had no sign of tumor recurrence after 3 years of follow-up. We
suggest that patients receiving MMC should have their blood pressure and renal function
closely monitored for the possibility of development of drug-induced renal insufficiency.
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Mitomycin C (MMC), an antibiotic isolated from
Streptomyces caespitosus, is an alkylating agent in
widespread use for the treatment of a variety of solid
tumors,  particularly those of the breast  and
gastrointestinal tract [1]. Adverse reactions to MMC
include myelosuppression [1], cardiotoxicity [1,2],
pulmonary toxicity [3], and nephrotoxicity [4–8].
Nephrotoxicity is characterized clinically by
microangiopathic hemolytic anemia, thrombo-
cytopenia, and renal insufficiency, which can be fatal
[4,5]. In the report of Hanna et al [5], the incidence was
9.79% and the mortality rate was 6.29%, which is
relatively high. This adverse reaction is probably dose-
related, with most cases having a total cumulative
dose of at least 60 mg/dL, and appears to be a delayed
phenomenon since renal function deterioration usually
becomes evident only either after several courses of
treatment or even several weeks after the end of therapy
[5,6,8].
We report  a case with typical  thrombotic
microangiopathy combined with unusual marked
ballooning of the glomerular tuft.
CASE PRESENTATION
A 58-year-old man underwent total gastrectomy for
adenocarcinoma of the stomach in January 1999. Intra-
abdominal lymph node metastasis was present at that
time. Adjuvant chemotherapy began in the following
month, at which time he was normotensive with normal
renal function and no proteinuria. Laboratory data
revealed a red blood cell (RBC) count of 4.5 x 106/mm3;
hemoglobin (Hb), 12 g/dL; hematocrit (Hct), 37%;
MCV (mean corpuscular volume), 82 fL; platelets, 260
x 103/mm3; lactate dehydrogenase (LDH), 132 IU/L;
blood urea nitrogen (BUN), 17 mg/dL; and creatinine
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(Cr), 1.0 mg/dL. MMC (10 mg) was given once a
month to a cumulative dose of 100 mg. The patient
developed anemia (Hb, 7.8–9.3 g/dL) in September,
while he was still on chemotherapy. Several blood
transfusions were given but renal function was not
tested at that time. Two months later, in late November,
he demonstrated progressive lower leg edema, fatigue,
and shortness of breath. Laboratory data showed a Cr
level of 3.4 mg/dL, Hb of 7.0 g/dL, and platelet count of
167 x 103/mm3; he was admitted.
Physical examination at admission revealed high
blood pressure (190/110 mmHg), signs of severe
anemia, and lower leg edema. There was no evidence
of tumor recurrence or metastasis in imaging studies,
including chest roentgenography, whole-body bone
scan, and abdominal computerized tomography.
Laboratory examinations at admission found an RBC
count of 2.17 x 106/mm3; Hb, 7.7 g/dL; Hct, 21.6%; white
blood cell count (WBC), 6,650/mm3 with normal
differential; platelets, 163 x 103/mm3; reticulocytes,
18%; BUN, 80 mg/dL; Cr, 3.9 mg/dL; serum albumin,
3.5 mg/dL; total bilirubin, 0.7 mg/dL; and LDH, 339 IU/L.
Proteinuria and hematuria were detected by urinalysis
and 24-hour urine collection contained 0.8 g protein.
Renal function test showed severe impairment, with
Cr clearance of 13 mL/minute. A percutaneous renal
needle biopsy was performed.
The biopsy specimen was prepared for light and
electron microscopy. For light microscopy, sections
were stained with hematoxylin and eosin, periodic
acid-Schiff, periodic acid silver methenamine (PASM),
and Masson’s  tr ichrome.  For ultrastructural
examination, fragments of tissue were fixed in
glutaraldehyde, post-fixed in osmium tetroxide,
embedded in epon, and stained with uranyl acetate
and lead citrate.
Thirty-four glomeruli were included in the light
microscopy specimen.  Some glomeruli  were
hypocellular with degenerative nuclear changes and a
smudged appearance (Figure 1). Other glomeruli
showed thickening of the capillary wall with a “double-
contour” pale space. The mesangial areas were
occasionally enlarged, where the matrix was loose and
reticulated on PASM staining. Some glomeruli
exhibited balloon-like dilatation of the glomerular
tufts, in which attenuated mesangial cells and ectatic
capillaries were observed (Figure 2). The interstitium
was diffusely widened due to both edema and fibrosis.
Many of  the tubular  cel ls  showed enlarged
hyperchromatic nuclei. Patchy tubular atrophy was
also noted.  Inf lammation was minimal .  The
interlobular arteries showed mucoid intimal thickening
and cellular proliferation resulting in an onion skin-
like change with marked narrowing of the vascular
lumen (Figure 3). There was no fibrin thrombus in the
glomeruli and arteries.
Electron microscopy revealed extensive widening
of the subendothelial space, which was filled with
electron-lucent, granular, or fibrillar material in all
five glomeruli examined (Figure 4). The mesangial
area was markedly edematous and displayed
disintegration of the matrix, indicating mesangiolysis.
Figure 1. Two glomeruli show fibrillary appearance, a decrease in
the number of nuclei, and mesangiolysis. The renal tubules are
atrophic, with many enlarged hyperchromatic nuclei (arrow).
(Hematoxylin & eosin, original magnification x 200.)
Figure 2. Ballooning of the glomerular tufts occupying about
one-half of the glomerular space. The rest of the tuft shows
collapsed capillary walls. (Periodic acid silver methenamine,
original magnification x 400.)
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No electron-dense deposit was found. The ballooned
tufts revealed enormous expansion of the subendothelial
space, filled with electron-lucent or finely granular
material, in which there were some RBCs.
Thrombotic microangiopathy was diagnosed based
on the histologic findings. From the patient’s history
and clinical manifestation, MMC-induced hemolytic-
uremic syndrome (HUS) was diagnosed. His renal
function deteriorated gradually, with serum Cr of
5.3 mg/dL 7 months after diagnosis. He was treated
with plasma exchange, antiplatelet agents, and
rigorous control of blood pressure. His blood pressure
was well controlled and renal function was stable,
with serum Cr of 4 mg/dL. He was followed for 3 years
and showed no sign of tumor recurrence.
DISCUSSION
The patient received adjuvant chemotherapy with
MMC alone after total gastrectomy. He developed
renal function impairment, anemia, and hypertension
9 months after initiation of chemotherapy. The clinical
manifestation was suggestive of HUS. There was no
sign of tumor recurrence or metastasis. The clinical
c o u r s e  w a s  c o n s i s t e n t  w i t h  M M C - i n d u c e d
nephrotoxicity.
HUS can arise spontaneously in patients with
advanced cancer [9,10]; however, it is more commonly
related to the use of certain chemotherapeutic agents
[5,9,11], of which MMC is the most common [6]. HUS
incidence after treatment with MMC is between 4%
and 15% [6,9].
The morphologic changes involved all four
compartments of the kidney: glomeruli, tubules,
vessels, and interstitium. The appearance of the
glomerular changes and mucoid intima thickening of
small-sized arteries were typical of HUS. Electron
m i c r o s c o p y  d e m o n s t r a t e d  l u c e n c y  o f  t h e
subendothelial space, characteristic of thrombotic
microangiopathy. However, two of the findings are
rarely seen in classic HUS, i.e. cellular atypia and
marked mesangiolysis. Nuclear atypia has been
associated with radiation therapy and treatment with
alkylating agents [12]. Cellular atypia can involve the
endothelium, mesangial cells, parietal and visceral
epithelial cells, and tubular epithelial cells. In patients
treated with low-dose MMC, renal anomalies are
usually limited to mild cellular atypia and mild
mesangiolyt ic  changes [6] .  Mesangiolysis ,  a
morphologic feature of HUS, is a known toxic effect of
Habu snake venom [13] and can be induced in
experimental animals. Particularly severe and
widespread mesangiolysis may be found in HUS
following bone marrow transplantation [14] or MMC
therapy [6]. The presence of mesangiolysis associated
with cellular dysplastic changes and microangiopathic
lesions are strongly suggestive of, and perhaps
pathognomonic of, MMC nephrotoxicity [6].
In the past, the prognosis of MMC-induced
nephrotoxicity has been poor, and the disease was
Figure 4. Widening of the subendothelial space filled with fibrillary
material. Some fragmented red blood cells are seen within the
capillary lumina. (Electron microscopy, original magnification
x 7,000.)
Figure 3. The glomerulus is hypocellular, with segmental ballooning
of the capillary tuft and mild increase of the mesangial matrix. The
interlobular artery is markedly stenotic due to intimal proliferation.
(Hematoxylin & eosin, original magnification x 200.)
Kaohsiung J Med Sci June 2003 • Vol 19 • No 6
M.C. Wen, C.H. Chen, and W.L. Ho
320
often fatal between 3 weeks and 8 months after the
beginning of clinical manifestation [5]. Recently,
however, the prognosis has improved, with some
patients surviving with partially recovered renal
function after treatment with plasma exchange,
antihypertensive agents, and antiplatelet agents [15,
16]. Our patient remained alive, with stable renal
function (serum Cr, 4 mg/dL) during the 3-year follow-
up period.
Since nephrotoxicity is dose-related and can be
delayed, high cumulative doses of MMC should be
avoided and the patient closely monitored for anemia
and any changes in renal function or blood pressure,
in order to detect nephrotoxicity early.
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